Ronald Lebofsky

TL;DR: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival and also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.

TL;DR: Cell‐free tumor DNA analysis is a potential alternative and/or replacement to analyses using costly, harmful and lengthy tissue biopsies of metastasis, irrespective of cancer type and metastatic site, for multiplexed mutation detection in selecting personalized therapies based on the patient's tumor genetic content.

TL;DR: CtDNA and CTC are correlated and both have poor prognostic significance but, in patients with detectable mutations, ctDNA was more frequently detected than CTC and has possibly more prognostic value.

TL;DR: In this article, the authors used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTC detection rates and prognostic value in metastatic TNBC patients.

TL;DR: A new generation of the Ephesia cell capture technology optimized for CTC capture and genetic analysis is presented, characterized in depth and compared with the CellSearch system as a reference.